DE102004052707A1 - Sweat reducing cosmetic preparation - Google Patents
Sweat reducing cosmetic preparation Download PDFInfo
- Publication number
- DE102004052707A1 DE102004052707A1 DE102004052707A DE102004052707A DE102004052707A1 DE 102004052707 A1 DE102004052707 A1 DE 102004052707A1 DE 102004052707 A DE102004052707 A DE 102004052707A DE 102004052707 A DE102004052707 A DE 102004052707A DE 102004052707 A1 DE102004052707 A1 DE 102004052707A1
- Authority
- DE
- Germany
- Prior art keywords
- sweat
- nkcc1
- glands
- cosmetic preparation
- sweat glands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004243 sweat Anatomy 0.000 title description 13
- 239000002537 cosmetic Substances 0.000 title description 2
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 claims abstract description 12
- 108091006620 SLC12A2 Proteins 0.000 claims abstract description 12
- 230000037427 ion transport Effects 0.000 claims abstract description 5
- 230000001413 cellular effect Effects 0.000 claims abstract description 4
- 239000003112 inhibitor Substances 0.000 claims abstract description 4
- 210000000106 sweat gland Anatomy 0.000 claims description 15
- 229960004064 bumetanide Drugs 0.000 claims description 7
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 7
- 229960003883 furosemide Drugs 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 102000034534 Cotransporters Human genes 0.000 description 3
- 108020003264 Cotransporters Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003754 zirconium Chemical class 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 101000640900 Danio rerio Solute carrier family 12 member 2 Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000008145 Sodium-Potassium-Chloride Symporters Human genes 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 101000640897 Squalus acanthias Solute carrier family 12 member 2 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 230000010222 extracellular calcium influx Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 108010006325 sodium-translocating ATPase Proteins 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Verwendung von Modulatoren und/oder Inhibitoren NKCC1 zur Beeinflussung des zellulären Ionentransportes.Use of modulators and / or inhibitors NKCC1 for influencing the cellular ion transport.
Description
Als klassische Antitranspirantien werden vor allem Aluminiumsalze oder Aluminium-/Zirkonium-Salze verwendet. Diese hemmen den Schweißfluss durch Verstopfung der Ausführungsgänge der Schweißdrüsen. Daher kann es zu einem Stau des Schweisses innerhalb der Drüse kommen. Darüber hinaus können solche Aluminiumsalze wie Aluminiumhydroxychloride bei häufiger Anwendung und empfindlichen Personen Hautschäden hervor rufen. Darüber hinaus kann es durch den Einsatz der Aluminiumsalze zu Verfärbungen von Textilien kommen, die mit dem Antitranspirans in Kontakt kommen.When classic antiperspirants are mainly aluminum salts or Aluminum / zirconium salts used. These inhibit the flow of sweat by obstructing the Excretory ducts of the sweat glands. Therefore There may be a congestion of sweat within the gland. Furthermore can such aluminum salts as Aluminiumhydroxychloride with frequent use and sensitive persons cause skin damage. Furthermore It may cause discoloration through the use of aluminum salts come from textiles that come into contact with the antiperspirant.
Zusätzlich zu den bislang eingesetzten Aluminium-/Zirkonium-Salzen sollen neue Wirkansätze gefunden werden, mit denen idealerweise der Schweiß effektiver und hautverträglicher unterdrückt werden kann. Hierbei ist das Ziel, nicht nur wie bisher den Schweißausfluss zu blockieren, sondern bereits die Bildung des Primärschweißes zu unterbinden.In addition to The aluminum / zirconium salts used so far are expected to be new Active approaches found which, ideally, make sweat more effective and more skin-friendly be suppressed can. Here is the goal, not just as before the sweat outflow to block, but already to prevent the formation of the primary sweat.
Der Mensch weist ca. 2 – 3 Mio. Schweißdrüsen am ganzen Körper auf. Ihre größte Dichte findet sich unter der Achsel und an Hand- und Fußflächen. Pro Tag werden 0,5 – max. 10 l Schweiß abgegeben.Of the Man has about 2 - 3 Million sweat glands all over body on. Your biggest density can be found under the armpit and on the palms and feet. Per day 0.5 - max. 10 l sweat.
Die
Innervation der ekkrinen Schweißdrüse erfolgt
ausgehend vom nervalen Stimulus über
die peripheren vegetativen Nerven des Sympathikus. Die Signalübertragung
von der Nerven- zur
Schweißdrüsenzelle
wird jedoch nicht wie üblich über Catecholamine
sondern über
den Neurotransmitter Acetylcholin (ACh) vermittelt (Sato et al.,
1989). Die durch das entsprechende Aktionspotenzial ausgelöste Depolarisation
der synaptischen Membran führt zur Öffnung Potenzial-abhängiger Kalzium-Kanäle. Der
darauffolgende extrazelluläre
Kalzium-Einstrom triggert die Exocytose der Acetylcholin-haltigen
synaptischen Vesikel. Die daraufhin in den synaptischen Spalt ausgeschütteten Neurotransmitter
binden an den G-Protein-gekoppelten
muskarinischen Acetylcholinrezeptor der Schweißdrüsen-zelle (
Eine
wesentliche Rolle beim Aufbau des Ionengradienten spielt der Na-K-Cl-Cotransporter (
Es hat sich nun überraschend und für den Fachmann nicht vorhersehbar herausgestellt, dass die Verwendung von Modulatoren und/oder Inhibitoren NKCC1 zur Beeinflussung des zelluären Ionentransportes den Nachteilen des Standes der Technik abhilft. Dabei ist es besonders bevorzugt, wenn Bumetanid oder Furosemid zur Beeinflussung des zelluären Ionentransportes eingesetzt wird. Weiter ist es besonders bevorzugt, wenn Sojaextrakt zur Inhibition der Schweißbildung von Schweißdrüsen, insbesondere menschlichen Schweißdrüsen verwendet wird.It has now become surprising and for the expert unpredictably pointed out that the use of modulators and / or inhibitors NKCC1 for influencing the zelluären Ion transport helps the disadvantages of the prior art. It is particularly preferred if Bumetanide or furosemide for influencing the cellular Ion transport is used. Furthermore, it is particularly preferred if soy extract to inhibit the sweat formation of sweat glands, in particular used human sweat glands becomes.
Eine Hemmung des Cotransporters unterbindet den Aufbau des Ionengradienten und des damit verbunden osmotischen Gefälles. Als Folge dessen erfolgt ein deutlich reduzierter Wassereinstrom von der basolateralen Seite der Zelle zum Lumen der Schweißdrüse hin. Analoge Vorgänge spielen sich auch in der Niere ab. Hier kann durch Blockierung des dort vorkommenden Na-K-Cl-Cotransporters (NKCC2) durch z.B. Bumetanid der Wassertransport inhibiert werden, was in Form von Diuretika auch therapeutisch getan wird. Die Inhibitoren bzw. Modulatoren des Na-K-Cl-Cotransporter 1, wie z.B. Bumetanid und Furosemid, sind für den kosmetischen Einsatz als Antitranspirantien geeignet.A Inhibition of the cotransporter prevents the formation of the ion gradient and the associated osmotic gradient. As a result of this occurs a significantly reduced influx of water from the basolateral side the cell to the lumen of the sweat gland. Analogous processes also take place in the kidney. Here can by blocking the occurring there Na-K-Cl cotransporter (NKCC2) by e.g. bumetanide the water transport can be inhibited, resulting in the form of diuretics is also done therapeutically. The inhibitors or modulators Na-K-Cl cotransporter 1, e.g. Bumetanide and Furosemide, are for the cosmetic use suitable as antiperspirants.
Darüber hinaus
wurde folgendes herausgefunden:
In den Schweißzellen
hemmt Bumetanid die Schweißsekretion.
Bumetanid
beeinflußt
die NaCl-Sekretion in den Sekretdrüsen.
Strukturen, die das
NKCC1 beeinflussen, können
zur Behandlung einer übermäßigen Schweißabsonderung
an den Handflächen
(Hyperhidrose) eingesetzt werden.In addition, the following was found:
In the sweat cells, bumetanide inhibits sweat secretion.
Bumetanide affects NaCl secretion in the secretory glands.
Structures that affect NKCC1 can be used to treat excessive perspiration on the palms (hyperhidrosis).
Immunhistochemische und immunelektronenmikroskopische Lokalisierung von NKCC1Immunohistochemical and immunoelectron microscopic localization of NKCC1
Die immunhistochemische Analyse zeigte eine starke NKCC1-Markierung der basal-lateralen Plasmamembranbereiche der Sekretdrüsen von Ratten und der menschlichen Schweißdrüsen, jedoch keine Markierung des apikalen Plasmamembranbereichs. Im Vergleich zu den Sekretdrüsen war die Markierung im Reabsorptionsgang signifikant reduziert. Anti-NKCC1-Antikörper haben die Epidermis nicht markiert. Ein identisches Markierungsmuster wurde in den Schweißdrüsen der Maus gefunden. Anti-NKCC2-Antikörper haben Schweißdrüsen nicht markiert, aber Kontrollnierenschnitte. Wir konnten das NKCC1 örtlich auf die basal-laterale Plasmamembran der Sekretzellen von Schweißdrüsen beschränken. Das weist darauf hin, dass ein NKCC-Protein an der Schweißbildung sowie an der Abheilung der Schrumpfung, die man in ekkrinen Klarzellen nach Schweißeinleitung beobachtet, beteiligt ist.Immunohistochemical analysis revealed strong NKCC1 labeling of the basal-lateral plasma membrane areas of the rat gland and human sweat glands, but no labeling of the apical plasma membrane area. Compared to the secretory glands, the labeling was significantly reduced in the Reabsorptionsgang. Anti-NKCC1 antibodies did not label the epidermis. An identical labeling pattern was found in the sweat glands of the mouse. Anti-NKCC2 antibodies did not label sweat glands, but control kidney cuts. We localized the NKCC1 locally to the basal-lateral plasma restrict the membrane of the secrets of sweat glands. This suggests that an NKCC protein is involved in sweat formation as well as healing of shrinkage observed in eccrine clear cells after sweat introduction.
Damit bestätigt diese Arbeit die Hypothese und erbringt den physiologischen Nachweis für eine NKCC1-Lokalisierung auf den sekretorischen Teil der Schweißdrüsen sowie für die Beteiligung von NKCC1 an der Absonderung von isotonischer Flüssigkeit. Es ist sehr wahrscheinlich, dass NKCC1 an der Cl--Akkumulation in den Drüsenzellen gegen den elektrochemischen Gradienten beteiligt ist, und diese Akkumulation wiederum kann mit der Bildung des Gradienten für Cl- zu tun haben und somit mit der Na+/H2O-Sekretion in den Schweiß wie auch in anderen exokrinen Drüsen.Thus, this work confirms the hypothesis and provides the physiological evidence for NKCC1 localization to the secretory portion of the sweat glands and for the involvement of NKCC1 in the secretion of isotonic fluid. It is very likely that NKCC1 is involved in Cl - accumulation in the glandular cells against the electrochemical gradient, and this accumulation, in turn, may have to do with the formation of the gradient for Cl - and thus with the Na + / H 2 O- Secretion in the sweat as well as in other exocrine glands.
Schlussfolgernd konnten wir feststellen, dass NKCC1 in der basal-lateralen Plasmamembran von menschlichen Sekretdrüsen vorkommt, wo es wahrscheinlich für die Bumetanid-sensitive Sekretion von NaCl verantwortlich ist.In conclusion we could conclude that NKCC1 is present in the basal-lateral plasma membrane of human secretory glands occurs where it is likely for the bumetanide-sensitive secretion of NaCl is responsible.
Literaturliterature
- Quinton, P. M. E., H. Y.; Mc Ewan Jenkinson, D.; Bovell, D. L. Structure and Function of Human Sweat Glands. In Antiperspirants and Deodorants, pp. 17-51Quinton, P.M.E., H.Y .; Mc Ewan Jenkinson, D .; Bovell, D.L. Structure and Function of Human Sweat Glands. In antiperspirants and deodorants, pp. 17-51
- Sato, K., Kang, W. H., Saga, K., and Sato, K. T. (1989). Biology of sweat glands and their disorders. I. Normal sweat gland function, J Am Acad Dermatol 20, 537-563Sato, K., Kang, W.H., Saga, K., and Sato, K.T. (1989). Biology of sweat glands and their disorders. I. Normal sweat gland function, J Am Acad Dermatol 20, 537-563
Claims (3)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004052707A DE102004052707A1 (en) | 2004-10-22 | 2004-10-22 | Sweat reducing cosmetic preparation |
| EP05801499A EP1804840A1 (en) | 2004-10-22 | 2005-10-21 | Sweat-reducing cosmetic preparation |
| PCT/EP2005/055448 WO2006042863A1 (en) | 2004-10-22 | 2005-10-21 | Sweat-reducing cosmetic preparation |
| JP2007537284A JP2008517039A (en) | 2004-10-22 | 2005-10-21 | Antiperspirant cosmetic formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004052707A DE102004052707A1 (en) | 2004-10-22 | 2004-10-22 | Sweat reducing cosmetic preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102004052707A1 true DE102004052707A1 (en) | 2006-04-27 |
Family
ID=35502618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102004052707A Withdrawn DE102004052707A1 (en) | 2004-10-22 | 2004-10-22 | Sweat reducing cosmetic preparation |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1804840A1 (en) |
| JP (1) | JP2008517039A (en) |
| DE (1) | DE102004052707A1 (en) |
| WO (1) | WO2006042863A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022258385A2 (en) | 2021-06-07 | 2022-12-15 | Unilever Ip Holdings B.V. | Compositions and methods for controlling sweat production |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019375A (en) * | 1989-03-14 | 1991-05-28 | The Procter & Gamble Company | Low residue antiperspirant creams |
| US6309657B2 (en) * | 1999-02-12 | 2001-10-30 | The Procter & Gamble Company | Cosmetic compositions |
| JP3661981B2 (en) * | 1999-06-09 | 2005-06-22 | 株式会社ノエビア | Antiperspirant |
| JP4033605B2 (en) * | 2000-06-19 | 2008-01-16 | ライオン株式会社 | Aerosol antiperspirant composition |
| US20060088537A1 (en) * | 2002-04-11 | 2006-04-27 | Terrett Jonathan A | Protein involved in cancer |
| DE10260954A1 (en) * | 2002-12-20 | 2004-07-01 | Henkel Kgaa | Arylsulfatase inhibitors in deodorants and antiperspirants |
| DE60309027T2 (en) * | 2003-08-26 | 2007-05-10 | Johnson & Johnson Consumer France Sas | Stabilized antiperspirant agent containing soy products |
| DE102004006829A1 (en) * | 2004-02-09 | 2005-08-25 | Beiersdorf Ag | Cosmetic composition for e.g. preventing or treating acne or sebum production contains actives combination of isoflavones and antiperspirants |
-
2004
- 2004-10-22 DE DE102004052707A patent/DE102004052707A1/en not_active Withdrawn
-
2005
- 2005-10-21 EP EP05801499A patent/EP1804840A1/en not_active Ceased
- 2005-10-21 WO PCT/EP2005/055448 patent/WO2006042863A1/en not_active Ceased
- 2005-10-21 JP JP2007537284A patent/JP2008517039A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022258385A2 (en) | 2021-06-07 | 2022-12-15 | Unilever Ip Holdings B.V. | Compositions and methods for controlling sweat production |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006042863A1 (en) | 2006-04-27 |
| JP2008517039A (en) | 2008-05-22 |
| EP1804840A1 (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434115T2 (en) | INHIBITOR OF THE GROWTH FACTOR FOR VITAL TREATMENT CELLS | |
| EP0500605B1 (en) | Cosmetic deodorants | |
| KR101858095B1 (en) | Cosmetic composition comprising Curcumae Longae Rhizoma extract comprising curcumin as an active ingredient for skin lightening, reducing wrinkle formation, and alleviating pruritus | |
| DE1467921A1 (en) | Process for the preparation of therapeutic or cosmetic agents for topical application | |
| Olsson et al. | The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury | |
| DE102004052707A1 (en) | Sweat reducing cosmetic preparation | |
| EP3463273A1 (en) | Non-ionic surfactants for reducing fatty tissue | |
| DE60026500T2 (en) | POLYPEPTIDE FROM STRATUM CORNEUM AND ITS USE | |
| WO2002100895A2 (en) | Antimicrobially active peptide | |
| JP2019530655A (en) | Use of Arbutus unedo fruit extract as cosmetics | |
| Baldwin | The fine structure of healing over in mammalian cardiac muscle | |
| DE60130802T2 (en) | AGONISTS AND ANTAGONISTS OF UROTENSIN-II | |
| Terlou et al. | The development of a hypothalamic monoaminergic system for the regulation of the pars intermedia activity in Xenopus laevis | |
| EP1169056A1 (en) | Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases | |
| DE60116478T2 (en) | USE OF CDP-CHOLIN FOR THE PROPHYLAXIS OF CEREBRAL ISCHEMIA | |
| Shen et al. | Differential modulatory effects of α-and β-adrenoceptor agonists and antagonists on cortical immediate–early gene expression following focal cerebrocortical lesion-induced spreading depression | |
| EP1054963B1 (en) | Sequences of an ih ionic channel and the use thereof | |
| WO2001027265A1 (en) | Nucleic acid sequences of hyperplasia and tumours of the thyroid | |
| WO2002017958A1 (en) | Agent for influencing angiogenesis | |
| Tsuda et al. | Synergistic effects of Bay K 8644 and bradykinin on norepinephrine release in the hypothalamus of spontaneously hypertensive rats | |
| Klee | Einfluss der Angst sowie Niedergeschlagenheit im stationären Aufenthalt auf das klinische Outcome von Patienten mit osteoporotischer, thorakolumbaler Wirbelkörperfraktur | |
| Beneit et al. | Effects of oxytocin on the isolated vas deferens of the rat | |
| Hattori et al. | Morphological Estimation of Brain Extracellular Fluid Dynamics in Cold‐induced Edema from the Aspect of Cerebrospinal Fluid‐Extracellular Fluid Communication | |
| DE102011052006A1 (en) | A cosmetic composition containing a particular water and its use as a depigmenting or anti-aging active ingredient | |
| Kurdow et al. | Vergleich der Apoptoseinduktion durch Gemcitabine und durch Todes-Rezeptor (CD95)-Aktivierung beim bronchialen Plattenepithelzellkarzinom in vitro und in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed |
Effective date: 20110905 |
|
| R120 | Application withdrawn or ip right abandoned | ||
| R120 | Application withdrawn or ip right abandoned |
Effective date: 20130920 |